Delivery of adjuvant sequential dose-dense FEC–Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence

H. Wildiers, R. Paridaens, Patrick Neven et al.|Breast Cancer Research and Treatment|2008

Cited by 30